In this study, we propose, for the first time, to test the safety and the potential efficacy of repeated allogenic Adipose tissue-derived Mesenchymal Stromal Cells IT injections in Primary Progressive Multiple Sclerosis patients.
Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017)
Age between 18 and 55 years
EDSS score: 3 to 6 at inclusion
Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit
Inflammatory activity during the past year (relapses or new T2 MRI lesions)
Disease Modifying Drugs during the past year
Treatment with high dose corticosteroids during the 30 days preceding the inclusion
Contra indication to lumbar puncture/intrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (<50 G/L), anticoagulant or fibrinolytic treatment
Rennes University Hospital
Lead sponsor
Etablissement Français du Sang
Collaborator